Literature DB >> 3501421

Ampicillin resistance in Haemophilus influenzae: identification of resistance mechanisms.

A J Reid1, I N Simpson, P B Harper, S G Amyes.   

Abstract

The incidence and mechanisms of ampicillin resistance (MIC greater than 1 mg/l) were investigated in 105 clinical isolates of Haemophilus influenzae collected in Edinburgh during 1983/4. Fifteen (14.3%) ampicillin-resistant strains were identified and these were non-serotypable and comprised six biotypes. Isoelectric focusing and beta-lactamase-inhibition studies demonstrated that production of the TEM-1 beta-lactamase was the principal mechanism of resistance in nine (60%) strains. Radiolabelling revealed that one beta-lactamase-positive strain also had an unusual penicillin-binding protein (PBP) profit. No beta-lactamase activity was detected in the other six (40%) ampicillin-resistant strains. Two beta-lactamase-negative ampicillin-resistant strains had atypical PBP profiles. SDS-PAGE analysis showed that four beta-lactamase-negative ampicillin-resistant strains, including one with altered PBPs, exhibited outer membrane protein profiles which differed from those of sensitive strains of the same biotype. The ampicillin-resistance mechanism of the remaining strain could not be determined. Thus, several resistance mechanisms, either acting individually or in combination, are implicated in ampicillin resistance in H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501421     DOI: 10.1093/jac/20.5.645

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae.

Authors:  F H Kayser; G Morenzoni; P Santanam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  Haemophilus influenzae: then and now.

Authors:  J Z Jordens; M P Slack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

3.  Rapid isoelectric focusing of plasmid-mediated beta-lactamases with Pharmacia PhastSystem.

Authors:  S Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

4.  Interpretive criteria for susceptibilities of Haemophilus influenzae to ampicillin, amoxicillin, and amoxicillin-clavulanic acid.

Authors:  P C Fuchs; A L Barry
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

5.  Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.

Authors:  Muneki Hotomi; Keiji Fujihara; Dewan S Billal; Kenji Suzuki; Tadao Nishimura; Shunkichi Baba; Noboru Yamanaka
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

6.  Molecular epidemiology of ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae.

Authors:  L Gazagne; C Delmas; E Bingen; H Dabernat
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

7.  In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens.

Authors:  K M Kumar; P Anitha; V Sivasakthi; Susmita Bag; P Lavanya; Anand Anbarasu; Sudha Ramaiah
Journal:  3 Biotech       Date:  2013-06-11       Impact factor: 2.406

8.  Novel Penicillin Analogues as Potential Antimicrobial Agents; Design, Synthesis and Docking Studies.

Authors:  Zaman Ashraf; Abdul Bais; Md Maniruzzaman Manir; Umar Niazi
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  Identification of Genome-Wide Mutations in Ciprofloxacin-Resistant F. tularensis LVS Using Whole Genome Tiling Arrays and Next Generation Sequencing.

Authors:  Crystal J Jaing; Kevin S McLoughlin; James B Thissen; Adam Zemla; Shea N Gardner; Lisa M Vergez; Feliza Bourguet; Shalini Mabery; Viacheslav Y Fofanov; Heather Koshinsky; Paul J Jackson
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.